Metsera has raised over $500 million in total funding, with promising Phase 1 results for its lead product and ongoing clinical trials.
Organizations Involved
Amneal Pharmaceuticals
Company Description
Metsera is a biotech startup focused on developing innovative treatments for obesity, including a long-acting GLP-1 injection and other obesity therapies. The company aims to improve existing obesity treatments and explore combination therapies for enhanced patient outcomes.
Market
Obesity treatment
Coinvestors
Wellington Management, Venrock Healthcare Capital Partners, Fidelity Management & Research, Janus Henderson Investors, T. Rowe Price